PROGRAM
LK-101
Personalized neoantigen
mRNA-DC vaccine
(Liver Cancer, Lung Cancer, Melanoma, Gastric Cancer)
DEVELOPMENT STAGE
Clinical Phase II
IND application
Pipeline
Advancing Precision Immunotherapy
Our pipeline translates neoantigen discovery into a growing portfolio of precision cancer immunotherapies across multiple therapeutic modalities.
PROGRAM
LK-201
Personalized neoantigen specific T cell therapy
reinfusion product
(Solid Tumor)
DEVELOPMENT STAGE
IIT application
PROGRAM
LK-502
Personalized neoantigen
mRNA-LNP vaccine
(Adjuvant & Advanced Solid Tumor)
DEVELOPMENT STAGE
IND application
PROGRAM
LK-503
Shared neoantigen
mRNA-LNP Vaccine
(Solid Tumor)
DEVELOPMENT STAGE
Early Development
EARLY PORTFOLIO
LK-301 · LK-401
TCE . Bispecific antibodies
and additional technologies
DEVELOPMENT STAGE
Early Research
| PROGRAM | THERAPEUTIC MODALITY | EARLY RESEARCH | IIT APPLICATION | IND APPLICATION | CLINICAL PHASE I | CLINICAL PHASE II |
|---|---|---|---|---|---|---|
| LK-101 | Personalized neoantigen mRNA-DC vaccine(Liver Cancer, Lung Cancer, Melanoma, Gastric Cancer) | Clinical Phase IIIND application | ||||
| LK-201 | Personalized neoantigen specific T cell therapy reinfusion product(Solid Tumor) | IIT application | ||||
| LK-502 | Personalized neoantigen mRNA-LNP vaccine(Adjuvant & Advanced Solid Tumor) | IND application | ||||
| LK-503 | Shared neoantigen mRNA-LNP Vaccine(Solid Tumor) | Early Development | ||||
| EARLY PORTFOLIOe.g, LK-301,LK-401 | TCE . Bispecific antibodies and additional technologies | Early Research | ||||
